A Review on Antiviral Activity of Favipiravir
Mariya Palathingal
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
M. Archana
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
K. Athulya Damodharan
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
. Nuaman
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
P. Ashisha
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
Akash Marathakam *
Department of Pharmaceutical Chemistry, National College of Pharmacy, Manassery, Mukkam Post, Kozhikode, Kerala-673602, India.
*Author to whom correspondence should be addressed.
Abstract
The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting in a larger pool of potential pharmacological targets. Favipiravir is included in the treatment regimen of many countries, including some regions of India, that have recently updated their treatment standards and is expected to be an effective treatment for SARS-CoV-2 infection, as it can be used to treat many different types of RNA virus infections such as Ebola, influenza, and the foot-and-mouth disease virus can be treated with this new nucleoside analogue. This review describes the status, mechanisms, pharmacokinetics, and antiviral effect of Favipiravir.
Keywords: Favipiravir, coronavirus, antiviral activity, toxicity